FEATURED

ZS: The Quarter That Beat and Still Broke

Zscaler reported after the bell on May 26. Revenue of $850.5 million. EPS of $1.08. ARR crossing $3.525 billion. Non-GAAP operating margin hitting an all-time high of 23%. By any reasonable scorecard, the quarter was excellent.

And yet, by the time Wednesday’s premarket session opened, ZS had cratered more than 21% — extending what had already been a -15% to -17% after-hours slide — for a combined session-over-session loss of approximately 24%. The worst single localized trading response of the fiscal year, on a quarter that cleared every growth metric the Street threw at it.

That disconnect is worth slowing down on. Because it tells you something specific about how institutional capital treats a high-multiple security software name heading into a fiscal year guide that implies a structural growth deceleration.

What the Report Actually Said

Let’s start with what was genuinely strong. Q3 FY2026 (quarter ended April 30, 2026) came in well above consensus across the board.

• Revenue: $850.5 million, up 25% year-over-year vs. analyst consensus of ~$835.7 million — a beat of roughly $14.8 million
• Non-GAAP EPS: $1.08, vs. the $1.01 consensus — a $0.07 beat, or roughly 6.9% above expectations
• ARR: $3.525 billion, up 25% year-over-year; organic ARR growth (excluding the Red Canary acquisition) came in at 21%
• Non-GAAP operating margin: 23% — an all-time high for the company, up from 22% in Q3 FY2025
• Gross margin: 80.7% — expanded meaningfully on operational leverage
• Deferred revenue: $2.477 billion as of April 30, 2026, up 25% year-over-year
• Remaining Performance Obligations (RPO): $6.459 billion — up significantly, signaling forward contract visibility
• Free cash flow: $136.0 million for the quarter, or 16% of revenue — down from 18% of revenue in Q3 FY2025, though up 14% in absolute dollars year-over-year

Q4 revenue was guided to $875 million–$878 million — just below the Street’s $878.6 million consensus. On EPS, however, Q4 guidance of $1.08–$1.09 cleared consensus estimates of $1.03 by a meaningful margin. Full-year FY2026 revenue was raised to $3.3295 billion–$3.3325 billion (24.6%–24.7% growth), up from the prior guide of $3.309 billion–$3.322 billion.

Here’s the part people are skipping: the surface-level numbers were fine. The damage was on the two disclosures that followed.

The Two Disclosures That Moved the Stock

First: Sales leadership departures. CFO Kevin Rubin disclosed during the call that two sales leaders exited the company at the end of Q3. Management was not specific about seniority or whether the departures were voluntary. What they were clear about: the company is taking a, in Rubin’s words, “prudent approach to guidance during this transition.” That’s careful language for a real problem — and the Street read it that way immediately.

Evercore ISI didn’t wait long. The firm downgraded ZS from Outperform to In Line Wednesday morning, cutting its price target from $225 to $155 — citing the sales leadership changes and the weaker-than-expected FY2027 outlook as the core rationale. Morgan Stanley adjusted its price target from $155 to $145 while holding Equalweight, flagging increased competition in the SASE space and challenges in new logo acquisition. TD Cowen moved to $180 from $220. Barclays dropped to $170 from $180. Baird held its Outperform but trimmed from $265 to $230.

Second — and more structurally significant: The FY2027 preliminary guide. Management offered an early look into fiscal year 2027, projecting revenue and ARR growth of approximately 16%–17% year-over-year. That’s a hard number to absorb. FY2026 was tracking at 24%–25% growth. The Street was modeling roughly 18.6% ARR growth and 19.5% revenue growth for FY2027 — the preliminary guide came in 5–8 percentage points below both. Consensus FY2027 revenue had been running somewhere around $3.95 billion–$4.0 billion; management guided $3.87 billion–$3.93 billion.

This is not about Q3 execution — Q3 was clean. What changed is the terminal velocity of the model, and when that shifts for a name trading at a meaningful premium to free cash flow, the repricing in the options and equity markets happens quickly and without mercy.

The Free Cash Flow Problem

Layered on top of the FY2027 deceleration guide was a material cut to the full-year FY2026 free cash flow margin outlook. Zscaler revised its FCF margin guidance down to approximately 22.8%–23.3%, from the prior framework of 26.5%–27%. The driver: capital expenditure moving to the high single-digits as a percentage of revenue, with management citing hardware costs tied to expanding AI-era infrastructure — including data center and Zero Trust Branch appliances.

To put that in context: Q3’s actual FCF margin came in at 16% of revenue, down from 18% in Q3 FY2025. Operating cash flow was $198.0 million, also down from $211.1 million in the year-ago quarter. The company described pulling forward some planned investments into Q4 as a partial explanation — but the full-year guidance revision was the sharper signal. A 350–420 basis point reduction in expected FCF margin is not a rounding error at this valuation level.

And here’s where it gets interesting: ZS came into this report carrying a 52-week high of $336.99 — hit back in late 2025 — against a pre-earnings close around $188. The stock had already retraced sharply, was trading more than 18% below its 2025 peak even before the quarter dropped. The May rally had pushed shares up roughly 27%–28% in a single month heading into earnings. Expectations were, by any measurement, elevated again.

Expectations vs. Reality — The Full Frame

Before the print, the options market had priced in a move of approximately 12.3%–14% based on the at-the-money straddle on the May 29 weekly series — the 182.50 strike straddle was pricing a 14% move, with call-to-put flow running roughly 1.5:1. Pre-earnings options volume was running 2.5x normal. The call skew suggested the dominant positioning was directionally long into the report.

What actually happened: a -15% to -17% after-hours slide that deepened to over -21% in Wednesday’s premarket session, reaching as low as $145.60 before some stabilization. The combined move — approximately 24% from the prior session’s close — blew past the implied move in both direction and magnitude. It’s worth noting this mirrors the company’s historical pattern: across the 11 most recent earnings releases, ZS beat estimates and still produced an average same-day decline of -4.91%. One of the largest beats in the company’s history — Q4 FY2024, where revenue beat by 27.54% — triggered an -18.67% drop. The market’s allergic reaction to beats is a feature of ZS’s trading behavior, not a bug.

The structural asymmetry is real: for a stock trading at elevated multiples on growth expectations, a forward guidance guide-down doesn’t just reduce the numerator in a DCF — it calls into question whether the multiple itself was warranted at all.

Sector Context

Slight tangent, but it matters for how you frame the ZS move: cybersecurity software as a group has been under steady pressure from the view that AI tooling will eventually commoditize elements of the enterprise security stack. That view hasn’t fully materialized operationally — Zscaler’s own AI Protect suite surpassed $100 million in bookings, and CEO Jay Chaudhry has been consistent about the AI tailwind for Zero Trust architecture — but it’s created a persistent valuation overhang across the sector. PANW, CRWD, and OKTA have all faced versions of the same macro question: what does the competitive landscape look like in three years, and can these platforms grow into their multiples?

ZS’s FY2027 deceleration guide lands directly into that debate. A 16%–17% grower with elevated CapEx and a leadership transition is a materially different investment thesis than the 24%–25% platform that analysts had been modeling into year-end. The Security industry currently sits in the bottom 40% of Zacks industry rankings — so the sector-level headwind is real and not unique to ZS.

Options Market Analysis

Going into May 26, IV was running hot. The May 29 weekly 182.50 straddle priced a ~14% move — call/put flow at 1.5:1. By all accounts, the options market was leaning toward a positive outcome. Post-report, that positioning was badly wrong-sided for longs.

With ZS now trading sharply lower and a multi-day volatility reset underway, what happens to IV matters. Post-event crush is the standard dynamic: IV typically collapses after the event resolves, even when the move is large. For traders looking at the options market now, the question is not whether IV is elevated on an absolute basis — it probably is — but whether you’re paying for residual uncertainty that’s already been priced into the stock price itself.

Key options considerations for traders following this situation:

• IV environment: Elevated pre-event; expect significant IV crush post-report across near-term expirations. New positioning should account for the crush dynamic, favoring defined-risk structures over long premium outright.
• Expected move reference: Options had priced a ~12.3%–14% move. The actual move was nearly double the implied range, which means short gamma positions (sold straddles, iron condors, naked short puts) took significant damage.
• Put/Call behavior: Pre-earnings flow was 1.5 calls to 1 put — decisively long-biased. Post-report, expect the ratio to shift as protective put buying increases and call selling accelerates in the $160–$175 range.
• Defined-risk bias: Given the combination of elevated residual uncertainty (sales leadership transition, FY27 guide ambiguity) and the recent 24% price dislocation, risk-defined structures are the appropriate framework for any new positioning in either direction.

Structured Trade Framework

The following frameworks are for analytical purposes only. These are not trade recommendations. All options involve risk, including the potential loss of the entire amount invested.

• Bull Case — “The Guide Is Sandbagged”: If you believe the FY2027 deceleration guide is management de-risking around a known sales transition rather than a structural business inflection, the case is that consensus estimates get revised down, stabilize, and then ZS beats a lowered bar. Remaining performance obligations of $6.459 billion (up from $6.1 billion in Q2) suggest forward revenue visibility that is inconsistent with a permanent growth stall. A defined-risk bull structure — such as a call spread in the $160–$180 range, targeting a 2–3 month recovery — keeps loss bounded while capturing upside if the transition resolves faster than feared. 47 analysts still carry a Buy or equivalent rating; consensus 12-month price target was $205+ pre-report.
• Bear Case — “The Deceleration Is Structural”: If you believe the FY2027 guide of 16%–17% reflects genuine market saturation, competitive pressure from Palo Alto Networks’ platformization strategy, and a degradation in new logo acquisition that predates the sales leader exits — then the multiple needs to compress further. At $145–$150, ZS still trades at approximately 33–35x FY2027 non-GAAP EPS (using the revised ~$4.15–$4.40 range), which is not obviously inexpensive for a decelerating grower. A defined-risk bear structure — put spread targeting $130–$140 — captures the compression thesis with limited upside exposure. For traders expecting continued downside, this framework provides structural definition.
• Neutral Case — “Wait for the Reset”: For traders who see a legitimate two-sided uncertainty — whether the sales disruption is transitory vs. structural isn’t answerable today — a neutral-positioning framework makes sense. Short volatility structures, if entered after IV crush completes, capture the premium decay dynamic without requiring a directional call. An iron condor spanning the $135–$175 range over a 30–45 day window allows the underlying to settle while collecting premium on both wings. This framework is appropriate only after IV normalization, not before.

Risk Analysis

The risks are not symmetric here. They tilt toward continued pressure in the near term, with a recovery path that requires a specific set of conditions to materialize.

• Sales leadership disruption: Two senior exits under CRO Mike Rich at end of Q3, with management declining to confirm whether the departures were voluntary or involuntary. The downstream impact on pipeline and net new logo acquisition won’t be visible for at least one quarter, possibly two. This is an open question that cannot be resolved from the outside.
• FY2027 guide ambiguity: At 16%–17% projected growth, ZS would decelerate roughly 8 percentage points from current FY2026 pace. The Street had modeled closer to 19%–21%. Estimate revisions are coming — likely within 24–48 hours — and will put incremental pressure on price targets across the coverage universe.
• CapEx inflation: The FCF margin cut to 22.8%–23.3% (from 26.5%–27%) is a real impairment. The company cited hardware costs for AI infrastructure build-out, with CapEx moving to the high single-digits as a percent of revenue. If that cost structure persists into FY2027, the FCF yield argument — one of the primary bull-case pillars — weakens materially.
• Organic growth haircut: Q3 ARR grew 25% headline, but organic growth excluding Red Canary came in at 21%. Management raised the full-year ARR guide by $7 million — but noted it was driven entirely by outperformance from its Risk360 Cloud product, contributing approximately $13 million in net new ARR versus a $6 million prior expectation. The core platform’s contribution to net new ARR is more muted than the headline figure suggests.
• Insider selling: Over the prior three months, insiders sold $2.4 million worth of shares with zero purchases reported. In isolation, not determinative — but it aligns with the cautious tone embedded in the Q4 and FY2027 guide.
• Structural multiple compression: At $145–$150, the forward P/E on revised FY2027 estimates sits around 33–35x. For a business guiding 16%–17% growth with elevated CapEx and an unresolved sales disruption, that multiple requires the inflection story to materialize cleanly. Multiple expansion from this level requires both the sales execution recovery and the long-term AI security adoption theme to deliver ahead of schedule — that’s a lot of conditions.

Forward Outlook

What’s interesting here is that the long-term thesis hasn’t actually been destroyed — it’s been disrupted. There’s a difference.

Remaining performance obligations of $6.459 billion as of April 30, 2026 — growing meaningfully from Q2’s $6.05 billion — are not consistent with a company that’s losing. Deferred revenue of $2.477 billion, growing 25% year-over-year, represents actual contracted future cash flows, not aspirational pipeline. The AI Protect suite crossing $100 million in bookings and the announced intent to acquire Symmetry Systems to govern AI agent communication at scale are product-level developments that suggest Zscaler is actively expanding into adjacent surface area, not retreating.

The near-term problem is that the market is not pricing ZS on long-term product optionality right now. It’s pricing on a forward growth rate that just guided 5–8 points below expectations, into a sales execution transition, with a CapEx structure that’s compressing cash conversion. That’s the dominant variable for the next 2–3 quarters.

Q4 FY2026 results — due September 8, 2026 — will be the first real read on whether the sales transition is contained or spreading. Net new ARR, organic ARR growth excluding acquisitions, and FCF margin will be the three metrics that determine whether the FY2027 guide tightens back up or gets revised further downward. If you believe the former, the next two quarters look like an accumulation window. If you believe the latter, the risk/reward still isn’t favorable at $145–$150.

The market doesn’t need ZS to be perfect. It needs ZS to be predictable again. And that’s what was lost last night.

Tactical Checklist

• Verify actual close price May 27, 2026 — the combined AH + premarket move was approximately 24%; confirm the regular session close before sizing any position
• Watch analyst estimate revisions within 24–48 hours — FY2027 EPS consensus will likely be revised from ~$4.58 toward $4.15–$4.40; price targets will compress from the current $210–$230 range toward $150–$180 across the Street
• Track IV crush timing — wait for near-term implied volatility to normalize before entering premium-buying structures; post-event IV decay typically accelerates over the first 3–5 sessions after a major gap
• Monitor net new ARR and organic growth in Q4 — the key metrics are organic net new ARR (excluding Red Canary contribution), new logo count, and whether FCF margin improves sequentially off the Q3 base of 16%
• Watch for sales leadership replacement announcement — any naming of new leadership under CRO Mike Rich would be a meaningful positive catalyst; the absence of that announcement heading into Q4 earnings would reinforce the bear case
• Use defined-risk structures only — given the uncertainty around the sales transition timeline and the FY2027 guide, undefined-risk positions in either direction carry outsized tail exposure; size accordingly
• Next earnings date: September 8, 2026 (per company disclosure)

The irony of Q3 is that Zscaler executed almost flawlessly on the metrics that were visible. Record operating margin. Clean revenue beat. RPO expansion. The problem was what surfaced underneath — and what it implies about the next four to six quarters.

That question is still open.

This editorial is for informational and analytical purposes only. Nothing contained herein constitutes financial advice, a solicitation, or a recommendation to buy or sell any security. All options involve risk. Past performance is not indicative of future results. Data sourced from Zscaler SEC filings (Form 8-K, Form 10-Q), company press releases dated May 26, 2026, and publicly available analyst commentary as of May 27, 2026.